Wei Chang An pill alleviates 2,4,6-trinitro-benzenesulfonic acid-induced ulcerative colitis by inhibiting epithelial-mesenchymal transition process

Abstract

Objective: To investigate the inhibitory effect and mechanism of Wei Chang An pill (WCA) on ulcerative colitis (UC).
Methods: A 2,4,6-trinitro-benzenesulfonic acid (TNBS)-induced UC model was established, and WCA was administered orally for 1 week. Body weight, colon length, disease activity index (DAI) score, and colon mucosa damage index (CMDI) score were recorded. Cytokine expression in lipopolysaccharide (LPS)-stimulated THP-1 cells was evaluated to determine the anti-inflammatory effects of WCA and its active ingredients. Immunohistochemistry and immunofluorescence were performed to detect the expression of epithelial-mesenchymal transition (EMT) markers E-cadherin and vimentin in rat UC and WCA groups, and in Caco-2 cells stimulated with conditioned medium (CM) from THP-1 cells, with or without LPS or WCA.
Results: WCA significantly inhibited body weight loss, decreased DAI and CMDI scores, blocked colon length shortening, and improved histological damage in UC rats. Furthermore, both myeloperoxidase (MPO) activities and cytokine expression in UC tissues were significantly suppressed by WCA as well. In THP-1 cells, the mRNA expression of interferon-inducible protein (IP)-10, tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and NF-κB inhibitor α (IκBα) was significantly suppressed by WCA and its active ingredients. E-cadherin expression in UC rats and CM-stimulated Caco-2 cells was downregulated and vimentin expression was upregulated, whereas both were blocked when administered with WCA.
Conclusions: Our data showed that WCA alleviated UC progression by inhibiting inflammation-induced EMT progression.

Keywords

Epithelial-mesenchymal transition / Inflammation / Traditional Chinese medicine / Ulcerative colitis / Wei Chang An

References

[[1]] Kornbluth A Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105(3):501-523; quiz 524.

[[2]] Ordás I, Eckmann L, Talamini M, et al.Ulcerative colitis. Lancet 2012;380(9853):1606-1619.

[[3]] Loftus EV.Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-1517.

[[4]] Kaplan GG.The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015;12(12):720-727.

[[5]] Silverberg MS, Satsangi J, Ahmad T, et al.Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterology 2005;19(Suppl A):S5A-S36A.

[[6]] Friedrich M, Pohin M, Powrie F.Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity 2019;50(4):992-1006.

[[7]] Dinallo V, Marafini I, Di Fusco D, et al.Neutrophil extracellular traps sustain inflammatory signals in ulcerative colitis. J Crohns Colitis 2019;13(6):722-784.

[[8]] Hay ED.An overview of epithelio-mesenchymal transformation. Acta Anat 1995;154(1):8-20.

[[9]] Tahara T, Shibata T, Okubo M, et al.DNA methylation status of Epithelial-Mesenchymal Transition (EMT)-related genes is associated with severe clinical phenotypes in Ulcerative Colitis (UC). PLoS One 2014;9(10):e107947.

[[10]] Bressler B, Marshall JK, Bernstein CN, et al. Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015;148(5):1035-1058. e3.

[[11]] Gajendran M, Loganathan P, Jimenez G, et al.A comprehensive review and update on ulcerative colitis. Dis Mon 2019;65(12):100851.

[[12]] Feagan BG, Rutgeerts P, Sands BE, et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699-710.

[[13]] Chinese Pharmacopoeia Commission.Pharmacopoeia of People's Republic of China. Part 1 Beijing: China Medical Science Press, 2020.

[[14]] Hu J, Gao WY, Ling NS, et al.Antidiarrhoeal and intestinal modulatory activities of Wei-Chang-An-Wan extract. J Ethnopharmacol 2009;125(3):450-455.

[[15]] Wang L, Zhang JZ, Liu Z, et al.Anti-inflammatory activity of Weichang'an Pill. Chin Tradit Herb Drugs 2013;44(8):1017-1021.

[[16]] Zhang T, Wei W, Su XL, et al.Effect of Wei Chang'an Pill on Th17/Treg immune balance in mice with ulcerative colitis. Gastroenterology 2020;158(6):788-789.

[[17]] Zong SY, Pu YQ, Xu BL, et al.Study on the physicochemical properties and anti-inflammatory effects of paeonol in rats with TNBS-induced ulcerative colitis. Int Immunopharmacol 2017;42:32-38.

[[18]] Horváth K, Varga C, Berkó A, et al.The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur J Pharmacol 2008;581(3):315-323.

[[19]] Jia S, Chai L, Zhang J, et al.Wei Chang An pill regulates gastrointestinal motility in a bidirectional manner. Pharm Biol 2021;59(1):1452-1463.

[[20]] Ren T, Tian T, Feng X, et al.An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-κB signaling pathway. Sci Rep 2015;12(5):9047.

[[21]] Qu Z, Zhang J, Gao W, et al.Bidirectional effects of methanol extract of Wei-Chang-An pill on gastrointestinal transit and the spasmolytic activity on isolated rat jejunum. J Ethnopharmacol 2014;155(1):203-212.

[[22]] Dai RH, Zhang YY, Bi KS.Study on the compatibility of composite herbal medicines of the Zishen pill. China J Chin Mat Med 2004;29(9):897-899.

[[23]] Ishiguro K, Watanabe O, Nakamura M, et al.Inhibition of KDM4A activity as a strategy to suppress interleukin-6 production and attenuate colitis induction. Clin Immunol 2017;180:120-127.

[[24]] Sener TE.The effect of betulinic acid on TNBS-induced experimental colitis. Marmara Pharm J 2013;17(17):52-59.

[[25]] Bento AF, Marcon R, Dutra RC, et al.β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am J Pathol 2011;178(3):1153-1166.

[[26]] Gao W, Wang C, Yu L, et al.Chlorogenic acid attenuates dextran sodium sulfate-induced ulcerative colitis in mice through MAPK/ ERK/JNK pathway. Biomed Res Int 2019;4(18):6769789.

[[27]] Xie F, Zhang H, Zheng C, et al.Costunolide improved dextran sulfate sodium-induced acute ulcerative colitis in mice through NF-κB, STAT1/3, and Akt signaling pathways. Int Immunopharmacol 2020;5(12):106567.

[[28]] Zhou Q, Zhang WX, He ZQ, et al.The possible anti-inflammatory effect of dehydrocostus lactone on DSS-induced colitis in mice. Evid Based Complement Alternat Med 2020;1(30):5659738.

[[29]] Nemmar A, Al-Salam S, Beegam S, et al.In vivo protective effects of nootkatone against particles-induced lung injury caused by diesel exhaust is mediated via the NF-κB pathway. Nutrients 2018;10(3):263.

[[30]] Ali BH, Al-Salam S, Adham SA, et al.Testicular toxicity of water pipe smoke exposure in mice and the effect of treatment with nootkatone thereon. Oxid Med Cell Longev 2019;6(25):2416935.

[[31]] Jeong DY, Kim S, Son MJ, et al.Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review. Autoimmun Rev 2019;18(5):439-454.

[[32]] Peterson CG, Lampinen M, Hansson T, et al.Evaluation of biomarkers for ulcerative colitis comparing two sampling methods: fecal markers reflect colorectal inflammation both macroscopically and on a cellular level. Scand J Clin Lab Invest 2016;76(5):393-401.

[[33]] Ashrafi F, Kowsari F, Darakhshandeh A, et al.Composite lymphoma in a patient with ulcerative colitis: a case report. Int J Hematol Oncol Stem Cell Res 2014;8(4):45-48.

[[34]] Luo M, Luo Y.Imperatorin relieved ulcerative colitis by regulating the Nrf-2/ARE/HO-1 pathway in rats. Inflammation 2021;44(2):558-569.

[[35]] Wu Z, Zeng H, Zhang L, et al.Patchouli alcohol: a natural sesquiterpene against both inflammation and intestinal barrier damage of ulcerative colitis. Inflammation 2020;43(4):1423-1435.

[[36]] Strober W, Fuss I, Mannon P.The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117(3):514-521.

[[37]] Planell N, Lozano JJ, Mora-Buch R, et al.Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 2013;62(7):967-976.

[[38]] Lovisa S, Genovese G, Danese S.Role of epithelial-to-mesenchymal transition in inflammatory bowel disease. J Crohns Colitis 2019;13(5):659-668.

[[39]] Niv Y.Mucin gene expression in the intestine of ulcerative colitis patients: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016;28(11):1241-1245.

[[40]] Pierdomenico M, Palone F, Cesi V, et al.Transcription factor ZNF281: a novel player in intestinal inflammation and fibrosis. Front Immunol 2018;11(9):02907.

[[41]] Zhao X, Fan J, Zhi F, et al.Mobilization of epithelial mesenchymal transition genes distinguishes active from inactive lesional tissue in patients with ulcerative colitis. Hum Mol Genet 2015;24(16):4615-4624.

[[42]] Zhang HJ, Zhang YN, Zhou H, et al.IL-17A promotes initiation and development of intestinal fibrosis through EMT. Dig Dis Sci 2018;63(11):2898-2909.

RIGHTS & PERMISSIONS

2023 Acupuncture and Herbal Medicine